|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
|
US6221897B1
(en)
|
1998-06-10 |
2001-04-24 |
Aventis Pharma Deutschland Gmbh |
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
|
|
US6489366B1
(en)
|
1998-12-23 |
2002-12-03 |
G. D. Searle, Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
|
AU2003241629B2
(en)
*
|
1999-04-19 |
2005-06-16 |
Astrazeneca Ab |
An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
US20020061888A1
(en)
*
|
2000-03-10 |
2002-05-23 |
Keller Bradley T. |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
|
SE0003766D0
(sv)
*
|
2000-10-18 |
2000-10-18 |
Astrazeneca Ab |
Novel formulation
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002051396A1
(en)
*
|
2000-12-26 |
2002-07-04 |
Sankyo Company, Limited |
Pharmaceutical compositions containing cyclobutene derivatives
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
MY131995A
(en)
|
2001-09-08 |
2007-09-28 |
Astrazeneca Ab |
Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
|
|
US7202247B2
(en)
|
2001-12-19 |
2007-04-10 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
|
WO2003053368A2
(en)
|
2001-12-19 |
2003-07-03 |
Atherogenics, Inc. |
Chalcone derivatives and their use to treat diseases
|
|
US6852753B2
(en)
|
2002-01-17 |
2005-02-08 |
Pharmacia Corporation |
Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2004020421A1
(ja)
*
|
2002-08-28 |
2004-03-11 |
Asahi Kasei Pharma Corporation |
新規な４級アンモニウム化合物
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
JP4711953B2
(ja)
|
2004-02-27 |
2011-06-29 |
旭化成ファーマ株式会社 |
新規なベンゾチアゼピン及びベンゾチエピン化合物
|
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
|
LT3023102T
(lt)
|
2010-11-04 |
2018-09-25 |
Albireo Ab |
Ibat inhibitoriai, skirti kepenų ligų gydymui
|
|
CA2815698C
(en)
|
2010-11-08 |
2019-04-30 |
Albireo Ab |
A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
|
|
EA201891154A1
(ru)
|
2011-10-28 |
2019-02-28 |
ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи |
Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
|
|
EA038594B1
(ru)
|
2011-10-28 |
2021-09-21 |
Шайр Хьюман Дженетик Терапис, Инк. |
Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
|
|
US20140275090A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
|
RU2015139732A
(ru)
|
2013-03-15 |
2017-04-24 |
ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи |
Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни
|
|
JO3301B1
(ar)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
تعديلات بلورية على إيلوبيكسيبات
|
|
KR20220082931A
(ko)
|
2014-06-25 |
2022-06-17 |
이에이 파마 가부시키가이샤 |
고형 제제 및 그의 착색 방지 또는 착색 감소 방법
|
|
CN106794188B
(zh)
*
|
2014-09-28 |
2022-12-02 |
华辉安健（北京）生物科技有限公司 |
聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
|
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
WO2017138878A1
(en)
|
2016-02-09 |
2017-08-17 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
CN108601744B
(zh)
|
2016-02-09 |
2022-01-04 |
阿尔比里奥公司 |
口服考来烯胺制剂及其用途
|
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
CA3071285A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
Cholestyramine granules, oral cholestyramine formulations and use thereof
|
|
CA3071182A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
Cholestyramine pellets, oral cholestyramine formulations and use thereof
|
|
IL272941B2
(en)
|
2017-08-28 |
2023-03-01 |
Enanta Pharm Inc |
Antiviral agents for viral hepatitis b
|
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CN112449637B
(zh)
|
2018-06-05 |
2024-03-19 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
PL3810581T3
(pl)
|
2018-06-20 |
2025-04-28 |
Albireo Ab |
Modyfikacje kryształu odewiksibatu
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
EP3883570A4
(en)
|
2018-11-21 |
2022-07-13 |
Enanta Pharmaceuticals, Inc. |
FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
|
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
SMT202300020T1
(it)
|
2019-02-06 |
2023-03-17 |
Albireo Ab |
Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari
|
|
CA3127408A1
(en)
|
2019-02-06 |
2020-08-13 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
|
EP3923943B1
(en)
|
2019-02-12 |
2024-07-31 |
Mirum Pharmaceuticals, Inc. |
Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
|
|
TWI877263B
(zh)
|
2019-12-04 |
2025-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻二氮呯化合物及其作為膽酸調節劑之用途
|
|
CR20220315A
(es)
|
2019-12-04 |
2022-10-26 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
|
|
WO2021110886A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
AR120679A1
(es)
|
2019-12-04 |
2022-03-09 |
Albireo Ab |
Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
|
|
WO2021110884A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CA3158181A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CA3158276A1
(en)
|
2019-12-04 |
2021-06-10 |
Per-Goran Gillberg |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
WO2021110887A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
CN114761018B
(zh)
|
2019-12-04 |
2025-12-02 |
阿尔比里奥公司 |
苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
EP4188541B1
(en)
|
2020-08-03 |
2024-12-25 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CA3196488A1
(en)
|
2020-11-12 |
2022-05-19 |
Albireo Ab |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
|
CN112274648B
(zh)
*
|
2020-11-23 |
2022-10-14 |
郑州大学 |
一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法
|
|
EP4255565A1
(en)
|
2020-12-04 |
2023-10-11 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
TW202313579A
(zh)
|
2021-06-03 |
2023-04-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|
|
JP2025524362A
(ja)
|
2022-06-09 |
2025-07-30 |
アルビレオ・アクチボラグ |
肝炎の処置
|
|
TW202423921A
(zh)
*
|
2022-08-22 |
2024-06-16 |
美商安塔製藥公司 |
稠合的雜雙環抗病毒劑
|
|
WO2025146507A1
(en)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
WO2025146508A1
(en)
|
2024-01-05 |
2025-07-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|